-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Vaccines are currently recognized as one of the effective methods to prevent infectious diseases.
In recent years, with the advancement of medical technology and the continuous improvement of people's health awareness, the vaccine market is constantly rising
.
According to statistics, the size of China's vaccine market has increased from 24 billion yuan to 42.
5 billion yuan from 2016 to 2019
.
According to the current development trend, the industry predicts that with the continuous enrichment of vaccine varieties and the continuous improvement of accessibility, as well as the increase of per capita income and the increase of people’s awareness of vaccination, China’s vaccine market will continue to maintain a rapid growth trend in the future.
Will exceed 60 billion yuan
.
It is worth noting that in the context of the continuous expansion of the market, many companies have begun to accelerate their deployment in this field
.
Among them, Fosun Pharma is a microcosm of these companies
.
On October 26, Fosun Pharma issued an announcement stating that in order to enrich the vaccine product pipeline, it will expand the stock of bacterial vaccine products on the basis of the existing viral vaccine products
.
It is planned to use cash and 100% equity of Dalian Yalifeng as a controlling shareholder to acquire Antjin, with a total value of over 4 billion yuan
.
According to the data, Antkin is an enterprise focusing on the development and production of bacterial vaccine products.
It has a polysaccharide-protein multivalent conjugate patent and is applied to the 13-valent pneumococcal conjugate vaccine and the 24-valent pneumococcal conjugate vaccine under development
.
Analysis believes that the vaccine industry has high competition thresholds and strict product approvals
.
With the aging of the population, the need for epidemic prevention and control, and the awakening of public health awareness, its future performance is more certain.
While attracting more and more pharmaceutical companies to increase their layout, pharmaceutical companies that originally focused on the vaccine industry will also usher in More positive
.
It is reported that in the first half of 2021, enterprises such as Zhifei Biological, Watson Biological and Kangtai Biological have all achieved outstanding performance
.
Among them, Kangtai Biology maintained substantial growth in its performance in the first quarter of this year, achieving a net profit of RMB 25,152,600 attributable to shareholders of listed companies, a year-on-year increase of 937.
58%..
In the long run, the industry predicts that with the continuous increase of vaccine varieties and the continuous improvement of accessibility, as well as the increase of China's per capita income and the increasing awareness of people's vaccination, China's vaccine market will continue to maintain a rapid growth trend in the future
.
At the same time, capital will continue to increase the vaccine industry and help the development of the domestic innovative vaccine industry
.
It is understood that as early as July 20, Maikekang, a giant in the field of domestic innovative vaccines, announced that it has completed a round of financing of hundreds of millions of yuan.
This round of financing will help the company to carry out clinical research and new types of new rotavirus vaccine projects.
The application and clinical research of the shingles vaccine project, the promotion and expansion of the research and development of other product pipelines, and the start of the construction of the industrialization base; On July 6, Hualan Biological also submitted a listing prospectus to the Shenzhen Stock Exchange.
It is planned to publicly issue no more than 40.
01 million shares, accounting for no less than 10% of the total equity after the issuance.
It is planned to raise approximately 2.
495 billion yuan to promote the construction of vaccine projects
.
In general, the current development of the vaccine industry is very promising in the industry, and many pharmaceutical companies in China are also increasing their investment in vaccine product research and development
.
In this environment, the future development of the domestic vaccine industry is expected to be further improved and usher in a golden period of development
.
In recent years, with the advancement of medical technology and the continuous improvement of people's health awareness, the vaccine market is constantly rising
.
According to statistics, the size of China's vaccine market has increased from 24 billion yuan to 42.
5 billion yuan from 2016 to 2019
.
According to the current development trend, the industry predicts that with the continuous enrichment of vaccine varieties and the continuous improvement of accessibility, as well as the increase of per capita income and the increase of people’s awareness of vaccination, China’s vaccine market will continue to maintain a rapid growth trend in the future.
Will exceed 60 billion yuan
.
It is worth noting that in the context of the continuous expansion of the market, many companies have begun to accelerate their deployment in this field
.
Among them, Fosun Pharma is a microcosm of these companies
.
On October 26, Fosun Pharma issued an announcement stating that in order to enrich the vaccine product pipeline, it will expand the stock of bacterial vaccine products on the basis of the existing viral vaccine products
.
It is planned to use cash and 100% equity of Dalian Yalifeng as a controlling shareholder to acquire Antjin, with a total value of over 4 billion yuan
.
According to the data, Antkin is an enterprise focusing on the development and production of bacterial vaccine products.
It has a polysaccharide-protein multivalent conjugate patent and is applied to the 13-valent pneumococcal conjugate vaccine and the 24-valent pneumococcal conjugate vaccine under development
.
Analysis believes that the vaccine industry has high competition thresholds and strict product approvals
.
With the aging of the population, the need for epidemic prevention and control, and the awakening of public health awareness, its future performance is more certain.
While attracting more and more pharmaceutical companies to increase their layout, pharmaceutical companies that originally focused on the vaccine industry will also usher in More positive
.
It is reported that in the first half of 2021, enterprises such as Zhifei Biological, Watson Biological and Kangtai Biological have all achieved outstanding performance
.
Among them, Kangtai Biology maintained substantial growth in its performance in the first quarter of this year, achieving a net profit of RMB 25,152,600 attributable to shareholders of listed companies, a year-on-year increase of 937.
58%..
In the long run, the industry predicts that with the continuous increase of vaccine varieties and the continuous improvement of accessibility, as well as the increase of China's per capita income and the increasing awareness of people's vaccination, China's vaccine market will continue to maintain a rapid growth trend in the future
.
At the same time, capital will continue to increase the vaccine industry and help the development of the domestic innovative vaccine industry
.
It is understood that as early as July 20, Maikekang, a giant in the field of domestic innovative vaccines, announced that it has completed a round of financing of hundreds of millions of yuan.
This round of financing will help the company to carry out clinical research and new types of new rotavirus vaccine projects.
The application and clinical research of the shingles vaccine project, the promotion and expansion of the research and development of other product pipelines, and the start of the construction of the industrialization base; On July 6, Hualan Biological also submitted a listing prospectus to the Shenzhen Stock Exchange.
It is planned to publicly issue no more than 40.
01 million shares, accounting for no less than 10% of the total equity after the issuance.
It is planned to raise approximately 2.
495 billion yuan to promote the construction of vaccine projects
.
In general, the current development of the vaccine industry is very promising in the industry, and many pharmaceutical companies in China are also increasing their investment in vaccine product research and development
.
In this environment, the future development of the domestic vaccine industry is expected to be further improved and usher in a golden period of development
.
